openPR Logo
Press release

Congressional Hearings Focus on FDA’s Handling of Avandia

06-12-2007 12:42 PM CET | Politics, Law & Society

Press release from: The Lanier Law Firm

At a June 6, 2007, congressional hearing, the U.S. Food and Drug Administration was questioned on its handling of the dangers associated with GlaxoSmithKline’s diabetes drug Avandia.

Rep. Henry Waxman (D-Calif.), chairman of the Committee on Oversight and Government Reform, accused the FDA of being to lax in monitoring the safety of Avandia. He said the FDA never completed a required post-market study of the drug, constituting “a major failure of our system.”

“It’s about time someone recognizes the flaws in our drug approval and monitoring processes,” says W. Mark Lanier of The Lanier Law Firm in Houston. “It is far too easy for dangerous drugs to stay on the market simply because they are profitable.”

The hearings were prompted by a recent New England Journal of Medicine article suggesting that Avandia significantly increases the risk of heart attacks and cardiovascular death. The article analyzed several clinical trials comparing patients taking Avandia with those not using the drug. The results indicated Avandia increased patients’ chances of heart attack by 43 percent and cardiac-related death by 64 percent.

In response to the article, the FDA issued a Safety Alert advising patients to talk with their doctor about Avandia’s risks. Nearly seven million people worldwide have taken Avandia.

The Lanier Law Firm is currently investigating claims against Avandia and its manufacturer, GlaxoSmithKline. The firm’s Pharmaceutical Liability Practice Group has decades of experience representing clients who have been injured by dangerous drugs.

With offices in Houston and New York, The Lanier Law Firm is committed to addressing client concerns with effective and innovative solutions. The firm is composed of outstanding trial attorneys with decades of experience handling cases involving pharmaceutical liability, asbestos exposure, business fraud, serious personal injuries, product liability, and toxic exposure.

The Lanier Law Firm
www.lanierlawfirm.com

Houston Law Office
6810 FM 1960 West
Houston, Texas 77069
(713) 659-5200
(713) 659-2204 – Fax

New York Law Office
Lanier Law Firm, PLLC
Tower 56
126 East 56th Street, 6th Floor
New York, NY 10022
(212) 421-2800
(212) 421-2878 – Fax

Press contact:
Alan Bentrup
800-559-4534

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Congressional Hearings Focus on FDA’s Handling of Avandia here

News-ID: 22062 • Views:

More Releases for Avandia

Future and Growth of BRIC Diabetes Drugs Market by 2021
Diabetes drugs help in preventing complications and controlling blood glucose level in the blood. Some of the drugs used to treat type 2 diabetes are metformin, actos, avandia, lantus subcutaneous, and invokana. All drugs are administered orally except insulin, exenatide, liraglutide, and pramlintide. Insulin is delivered through insulin delivery devices including infusion pump, intravenous sets, insulin syringe, insulin pen, and jet injectors. Long acting, intermediate acting, short acting, and rapid
GlaxoSmithKline Agrees to Settlement in 20,000 Avandia Lawsuits
Nadrich & Cohen, LLP reports that GlaxoSmithKline has agreed to settle approximately 20,000 Avandia side effects lawsuits. Los Angeles, CA, February 3, 2012 – UK drug-maker GlaxoSmithKline has agreed to settle 20,000 Avandia side effects lawsuits. According to a Bloomberg report, the company previously agreed to pay at least $700 million to settle more than 15,000 claims on behalf of patients who said that the drug caused heart attacks, strokes
Pfizer Seeking Consolidation of Zoloft Birth Defects Lawsuits
Nadrich & Cohen, LLP reports that Pfizer is seeking to consolidate a number of federal Zoloft birth defects lawsuits into a multidistrict litigation. Los Angeles, CA, February 1, 2012 – Pfizer has reportedly asked a federal judicial panel to centralize a number of Zoloft birth defects lawsuits filed against the company. If the motion is granted, the cases would be consolidated for pretrial proceedings and heard in a federal district
Bristol-Meyers Squibb Sued by 72 Plaintiffs Over Plavix Side Effects
Nadrick & Cohen, LLP reports that 72 plaintiffs have joined together in a Plavix side effects lawsuit filed against Bristol-Meyers Squibb. Los Angeles, CA, January 27, 2012 – Seventy-two plaintiffs from across the country have joined together in filing a Plavix side effects lawsuit against the drug’s maker, Bristol-Meyers Squibb. According to the Madison Record, the plaintiffs are seeking an unspecified amount of compensation for injuries they say were caused
Nadrich & Cohen LLP Clarifies Statements Regarding Actos Bladder Cancer Lawsuits
Los Angeles, CA, January 24, 2012 – National law firm Nadrich & Cohen LLP would like to clarify previous statements regarding the pending Actos bladder cancer litigation. Earlier press releases included incorrect information regarding the total number of Actos lawsuits filed against the drug’s manufacturer, Takeda Pharmaceuticals. Those releases, based on media reports, estimated the number of lawsuits filed in state and federal courts nationwide in connection with Actos numbered
Federal Panel Votes to Consolidate Actos Bladder Cancer Lawsuits
Nadrich & Cohen LLP reports that a federal judicial panel has voted to consolidate pending Actos bladder cancer claims into a multidistrict litigation for pretrial proceedings. Los Angeles, CA, January 5, 2012 – Plaintiffs in the Actos bladder cancer litigation have successfully moved to have the federal lawsuits consolidated into a multidistrict litigation for pretrial proceedings. The cases will be transferred to the Western District Court of Louisiana, with the